Tetracosactin
PreclinicalSmall molecule
Tetracosactin is one of 11 small molecule programs targeting Autosomal Dominant Polycystic Kidney Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Autosomal Dominant Polycystic Kidney Disease
#DrugCompanyPhaseTrials
1Samsca
OtsukaApproved
Afinitor
NovartisApproved
Jardiance
Boehringer IngelheimApproved
Lanreotide Acetate
AAlbireo, an Ipsen Company
Approved
Lesinurad
EEsperion Therapeutics, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Sandostatin
Sun PharmaApproved
VX-407
Vertex PharmaceuticalsPhase 2
AZD1613
AstraZenecaPhase 1
Tripterygium Wilfordii
ZZhi-Hong Liu, M.D.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tetracosactin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIstanbul University